Meeting
2021 Genitourinary Cancers Symposium
Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.
Authors
Daniel M. Geynisman
Fox Chase Cancer Center, Philadelphia, PA
Daniel M. Geynisman , Andres F Correa , Chethan Ramamurthy , J Robert Beck , Elizabeth A. Handorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 53)
DOI
10.1200/JCO.2021.39.6_suppl.53
Abstract #
53
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.
First Author: Stephen J. Freedland
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.
First Author: Nataniel Hernan Lester-Coll
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of concomitant medications on treatment response and survival in de novo metastatic prostate cancer: Secondary analysis of the LATITUDE study.
First Author: Soumyajit Roy
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo